Systemic pharmacokinetics – drug–drug interaction context (PK-DDI)

The systemic pharmacokinetics – drug–drug interaction (PK-DDI) context refers to the pharmacological framework used to evaluate how the absorption, distribution, metabolism, and excretion (ADME) of a drug are modified by the co-administration of another substance (FDA, 2020). This is not a single molecular target but a systemic process involving multiple enzymes, such as the Cytochrome P450 (CYP) family, and transporters like P-glycoprotein (Zanger & Schwab, 2013). PK-DDIs are a major clinical concern because they can lead to significant changes in drug exposure, potentially resulting in toxicity or therapeutic failure (EMA, 2012). For example, the inhibition of CYP3A4 can drastically increase the plasma concentration of sensitive substrates, while induction can render a treatment ineffective. Understanding this context is essential for drug labeling, patient safety, and the management of polypharmacy (Hermann, 2003). Biotech analysts monitor PK-DDI profiles to assess the regulatory hurdles and competitive positioning of new chemical entities, as robust DDI characterization ensures that therapeutic windows are maintained across diverse patient populations.

Other names

Pharmacokinetic drug-drug interactionsPK-DDIMetabolic drug interactionsTransporter-mediated drug interactionsDrug-drug interaction (DDI)

Modulation of systemic drug exposure through the competitive or non-competitive inhibition or transcriptional induction of drug-metabolizing enzymes and membrane transporters.